# [Key points of perioperative whole-process management for patients with advanced gastric cancer].

**Tumor:** Cáncer gástrico/UGE
**Autores:** Zhu ZG
**Revista:** Zhonghua Wei Chang Wai Ke Za Zhi (2020)
**PMID:** 32074789 | **PMCID:** —
**DOI:** [10.3760/cma.j.issn.1671-0274.2020.02.004](https://doi.org/10.3760/cma.j.issn.1671-0274.2020.02.004)
**Fuente:** PubMed (abstract only)

## Relevancia
Cáncer gástrico/UGE tratado con quimioterapia perioperatoria (FLOT/MAGIC) o inmunoterapia: documenta downstaging ganglionar, valor pronóstico de ypN0 y rendimiento ganglionar tras NAC. Comparable al paradigma mamario: ypN0 tras quimioterapia neoadyuvante es marcador pronóstico fuerte y guía la linfadenectomía D2.

## Abstract
Perioperative whole-process management (WPM) for patients with advanced gastric cancer (AGC) mainly focuses on some clinical issues which are easily neglected or underappreciated. WPM is helpful in making a scientific and rational therapeutic plan, and avoiding inadequate communication in multi-disciplinary participation, so that the diagnosis, treatment and rehabilitation for AGC patients can be integrated organically. Based on the current clinical practice for AGC patients, eight key issues in WPM should be emphasized.(1) Preoperative clinical staging. An accurate preoperative staging by endoscopy and imaging technique is helpful in setting up a rational therapeutic plan, and is also a prerequisite to start WPM. (2) Indications and value of diagnostic laparoscopy. Laparoscopic exploration is beneficial to find intraperitoneal micro-metastases so as to avoid unnecessary laparotomy. For cases of AGC infiltrating serosal layer or suspected of peritoneal metastasis, preoperative laparoscopic exploration should be routinely performed. (3) Neoadjuvant therapy. Multiple RCT studies have shown that neoadjuvant chemotherapy can benefit a majority of patients with AGC, improving prognosis and prolonging their overall survival. Therefore, neoadjuvant therapy should be considered first for stage III and IVA AGC patients. (4) Prediction of efficacy in neoadjuvant chemotherapy. Endoscopy, MDCT scan, PET-CT and liquid biopsy have certain predictive value individually, which can be used together or separately to improve the accuracy of prediction. (5) Effective prevention of postoperative peritoneal metastasis. Extensive intraoperative peritoneal lavage (EIPL), neoadjuvant intraperitoneal and systemic chemotherapy (NIPS), hyperthermic intraperitoneal chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy (EPIC), and normothermic intraperitoneal chemotherapy (NIPEC) have been shown to be of various efficacy in preventing peritoneal metastases. (6) Prediction of postoperative prognosis of AGC patients. The key pathological indicators are tumor regression grade (TRG) and ypTNM staging, especially if there is lymph node metastasis. Usually for AGC patients who received neoajuvant chemotherapy with TRG 0 or ypN0, their prognosis was comparable to that of patients with cTNM stage I.(7) Postoperative adjuvant chemotherapy. Postoperative adjuvant therapy is always an important part of the WPM management of AGC patients. Several recent RCT studies have shown that duplet chemotherapy can significantly reduce the risk of death after D2 radical gastrectomy compared to singlet chemotherapy, especially for stage III patients. (8) Perioperative nutritional support. Due to different degrees of malnutrition in AGC patients, enhanced nutritional treatment in the perioperative period can not only reduce surgical complications, but also enable patients to complete necessary course of chemotherapy, and ultimately further improve their survival rate.

## Acceso
Vía [DOI](https://doi.org/10.3760/cma.j.issn.1671-0274.2020.02.004) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.3760/cma.j.issn.1671-0274.2020.02.004*
